Product Information
OXYBUTYNIN CL ER 5 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.0841 per EA under NDC 72888003005. Its NADAC has been published 91 times since Jan 8, 2025.
FDA first approved this application on Oct 27, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888003005
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214415FDA Approved
10/27/2020
TE Code
AB
On Market Since
10/27/2020
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 5 MG TABLET has been published 91 times since Jan 8, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0841 per EA |
|---|---|
| All-time high | $0.1030 (Apr 16, 2025) |
| All-time low | $0.0817 (Aug 19, 2026) |
| 52-week high | $0.0990 |
| 52-week low | $0.0817 |
| Median price | $0.0930 |
| Average price | $0.0929 |
| Largest weekly change | +10.7% (Feb 19, 2025) |
| Weeks tracked | 91 |
| Tracking since | Jan 8, 2025 |
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 43% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxybutynin Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 5 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.0841 per EA (NDC 72888003005), effective Sep 30, 2026.
How has the price of OXYBUTYNIN CL ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has held within roughly two percent of its current level. It has been tracked across 91 weekly CMS publications since Jan 8, 2025.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 5 MG TABLET?
Since Jan 8, 2025, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has ranged from a low of $0.0817 (Aug 19, 2026) to a high of $0.1030 (Apr 16, 2025), with a median of $0.0930 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 5 MG TABLET?
Yes. 14 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXYBUTYNIN 5 MG TABLET, is $0.0480 per EA — about 43% below OXYBUTYNIN CL ER 5 MG TABLET.
Who manufactures OXYBUTYNIN CL ER 5 MG TABLET?
OXYBUTYNIN CL ER 5 MG TABLET (NDC 72888003005) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.